Narcolepsy and idiopathic hypersomnia
Central disorders of hypersomnolence · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic disorders of excessive daytime sleepiness; narcolepsy type 1 features cataplexy and loss of hypocretin neurons, while type 2 and idiopathic hypersomnia lack cataplexy. Diagnosis requires sleep studies and management combines scheduled naps with stimulant and anticataplectic therapy.
Red flags
- Cataplexy triggered by emotion (status cataplecticus if abrupt withdrawal)
- Undiagnosed obstructive sleep apnoea
- Falls asleep driving
- Cardiovascular disease limiting stimulant use
- Severe mood disorder
Assessment
Differential diagnosis
- Obstructive sleep apnoea
- Insufficient sleep syndrome
- Depression and other mood disorders
- Idiopathic hypersomnia
- Circadian rhythm disorders
- Medication-induced sedation
Investigations
- Overnight polysomnography followed by multiple sleep latency test (MSLT)
- Epworth Sleepiness Scale
- CSF hypocretin-1 (low in narcolepsy type 1) in selected cases
- HLA-DQB1*06:02 typing (supportive, not diagnostic)
- Exclude sleep apnoea and insufficient sleep first
- Actigraphy/sleep diary to confirm adequate sleep opportunity
Management
- Establish chronic excessive daytime sleepiness and screen for cataplexy
- Exclude obstructive sleep apnoea and insufficient or shift-related sleep
- Confirm with polysomnography and MSLT (short sleep latency, sleep-onset REM periods)
- Measure CSF hypocretin where narcolepsy type 1 is suspected
- Advise scheduled short naps and strict sleep hygiene
- Start a wake-promoting agent for daytime sleepiness
- Add an anticataplectic agent for narcolepsy with cataplexy
- Consider sodium oxybate for severe sleepiness and cataplexy
- Counsel on driving, occupation and safety
- Arrange sleep-service follow-up and treat comorbidities
Drugs & doses
Modafinil 100-400 mg PO daily (wake-promoting)
Methylphenidate or dexamfetamine for refractory sleepiness
Pitolisant 4.5-36 mg PO daily (histamine H3 antagonist)
Solriamfetol 75-150 mg PO daily
Sodium oxybate 2.25-4.5 g per night in two divided doses (sleepiness and cataplexy)
Venlafaxine or clomipramine as anticataplectic alternatives
Disposition
Specialist sleep service. Driving advice per local regulations. Long-term pharmacological and behavioural management.
Complications & pitfalls
- Motor vehicle and occupational accidents
- Cataplexy-related injury
- Cardiovascular effects of stimulants
- Social and occupational impairment
- Depression and reduced quality of life
Exam pearls
- Sleep-onset REM periods on MSLT and low CSF hypocretin support narcolepsy type 1
- Always exclude obstructive sleep apnoea and insufficient sleep first
- Abruptly stopping anticataplectics can precipitate status cataplecticus
- Scheduled naps are a cornerstone of non-drug management
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.